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Imaging findings of adult-onset mitochondrial encephalomyopathy, lactic acidosis, and
stroke-like episodes (MELAS) syndrome is poorly documented. The authors present a 48-
year-old woman with subacute onset of word-finding difficulties and right arm stiffness.
Magnetic resonance imaging performed 2 weeks prior revealed left temporal lobe diffusion
and fluid-attenuated inversion recovery hyperintensity predominantly involving the cor-
tex. The apparent diffusion coefficient map showed preserved signal in the temporal
cortex. Subsequent magnetic resonance imagings demonstrated a new diffusion signal
abnormality extending to the left parietal cortex and occipital cortex with resolving
diffusion hyperintensity in the temporal lobe. MR spectroscopy showed scattered areas of
lactate deposition. Diagnosis of MELAS syndrome was confirmed by genetic analysis.
Fluctuating, migratory stroke-like lesions with a predilection for the parietal, temporal, and
occipital cortex that do not conform to a vascular territory and a lactate spike at 1.3 ppm on
MR spectroscopy are characteristic of MELAS syndrome. Preserved signal intensity on
apparent diffusion coefficient is useful to distinguish MELAS syndrome from ischemic
infarction where the signal is typically reduced.
© 2016 the Authors. Published by Elsevier Inc. under copyright license from the University
of Washington. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Case report
A 48-year-old woman of Palestine origin presented to a local
hospital with subacute onset of confusion and word-finding
difficulties. Her symptoms had started 2 weeks earlier with alared that no competing
and.edu (S.S. Cai).
Elsevier Inc. under copy
se (http://creativecommoheadache, nausea, and dizziness. Her medical history was
significant for essential hypertension, poorly controlled type 2
diabetes mellitus, and bilateral hearing loss of unknown eti-
ology requiring hearing aids since age 46 years. Computed to-
mography (CT) revealed a hypodense lesion within the leftinterests exist.
right license from the University of Washington. This is an open
ns.org/licenses/by-nc-nd/4.0/).
Fig. 1 e CT performed at t¼ 0 revealed hypodensity (edema) in the left temporal gray matter and white matter suggestive of
infarction.
R a d i o l o g y C a s e R e p o r t s 1 1 ( 2 0 1 6 ) 4 2 5e4 2 9426temporal lobe (edema) involving graymatter andwhitematter
(Fig. 1). Magnetic resonance imaging (MRI) demonstrated
left temporal lobe diffusion signal abnormality and
fluid-attenuated inversion recovery (FLAIR) hyperintensityFig. 2 e MRI examinations at t ¼ 0 and week 2 showing the mig
acidosis, and stroke-like episodes (MELAS). At t ¼ 0, there is co
hyperintensity with isointense signal on the ADC map. This le
temporal lobe, both anterior and posterior, to the original lesion
MRI.predominantly involving the cortex, with cortical and lep-
tomeningeal contrast enhancement. The apparent diffusion
coefficient (ADC) map showed preserved, isointense signal in
the temporal cortex (Fig. 2). The ventricular system andratory lesions of mitochondrial encephalomyopathy, lactic
rtical diffusion weighted imaging (arrowhead) and FLAIR
sion shows partial resolution with new lesions in the
with extension into occipital cortex (arrows) on the week 2
Fig. 3 e Normal patent vessels seen on MR angiogram at
t ¼ 0.
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vessels without stenosis were seen on MR angiogram (Fig. 3).
Clinically, her symptoms initially stabilized, but in the
following week, the patient's confusion worsened, and sheFig. 4 e MRI examinations showing interval progression from w
and new diffusion weighted imaging signal abnormality within
pattern of MELAS.developed clumsiness and stiffness of her right arm. At that
point, shewas referred toour institution for further evaluation.
On admission, she had moderate expressive aphasia, mild
dysarthria, and apraxia with paratonia of her right upper
extremity. Imaging showed partial resolution of the left tem-
poral lobe lesion, and new cortical diffusionweighted imaging
abnormality in the left temporal and occipital lobes with
corresponding FLAIR hyperintensity (Fig. 2). Normal ADC
signal and postcontrast leptomeningeal enhancement were
similarly seen in these regions. Positron emission tomography
(PET) showed no evidence of malignancy but demonstrated
reduced metabolic activity in the regions of signal abnormal-
ity with adjacent metabolic hyperactivity involving the left
superior parietal and medial occipital lobes in a gyriform
distribution. Lumbar puncture ruled out infection but was
significant for elevated lactate to 5.1 mmol/L. Serum lactate
was elevated to 4.6 mmol/L. Serum inflammatory markers
(dsDNA, anti-Hu, anti-Ri, anti-Yo, SS-A, SS-B, C3, C4) were
normal. On day 4 of hospitalization, the patient reported
feeling better, and her family took her home against medical
advice.
She then suffered 2 generalized toniceclonic seizures
associated with severe headache and blurred vision, and she
was readmitted to our institution the same night. Continuous
electroencephalogram showed left hemispheric slowing and
frequent seizures originating from the left occipital lobe.
Subsequent MRI demonstrated extension of the occipital
lesion to involve more of the parietal and occipital lobes
(Fig. 4). MR spectroscopy showed elevated lactate peak at 1.3eek 2 to 3. Week 3 shows a resolving temporal lobe lesion,
the occipital lobe (arrow) demonstrating the migratory
Fig. 5 e MR spectroscopy demonstrated elevation of the
lactate peak, seen as an inverse doublet at 1.3 (arrow),
within normal and abnormal regions of the brain.
R a d i o l o g y C a s e R e p o r t s 1 1 ( 2 0 1 6 ) 4 2 5e4 2 9428ppm diffusely throughout the brain (Fig. 5). A clinical diag-
nosis of MELAS syndrome was made.
The patient recovered without further complications on
anticonvulsants and high-dose intravenous arginine then oral
citrulline at 0.5 mg/kg. At 2-month follow-up, her cognition
including language and activities of daily living had greatly
improved. Genetic testing of patient's serum confirmed
m.3243 A/G mutation (heteroplasmy 22%) in the MT-TL1
gene that encodes leucine transfer RNA, consistent with
MELAS syndrome. A detailed 3-generation family history
revealed no known neurologic, muscular, cardiac, or vision
problems. Genetic counseling is ongoing.Discussion
Mitochondrial encephalomyopathy, lactic acidosis, and
stroke-like episodes syndrome are maternally inherited
multisystem disorder caused bymitochondrial DNAmutation
[1e3]. Several point mutations in themitochondrial DNA have
been identified. In particular, an A to G transition at nucleotide
position 3243 of the MT-TL1 gene that encodes transfer
RNALeu(UUR) is present in 80% of the patients with MELAS
syndrome [3]. Heteroplasmy within individual cells can result
in unpredictable distribution of abnormal mitochondria in
tissues and family members often inherited different per-
centage of mutant mitochondrial DNA. As such, constellation
of symptoms and severity of symptoms are highly variable [4].
Review of our patient's family history suggests that she is only
one who became symptomatic.
Pathophysiology of the disease is poorly understood. Cur-
rent theories include inadequate energy production, micro-
vascular angiopathy, and nitric oxide (NO) deficiency [5e8].
Tissues with high energy demand are particularly susceptible
to damage, such as the brain and skeletal muscles. Neurologic
symptoms ofMELAS syndrome typically present as stroke-likeepisodes and commonly include severe headache, sensori-
neural hearing loss, vision changes, expressive or receptive
aphasia, rapid cognitive decline, and seizures. Exercise intol-
erance and muscle weakness are often present, along with
lactic acidosis. While rare, systemic manifestations include
hypertrophic cardiomyopathy, ophthalmoplegia, focal
segmental glomerulosclerosis, and diabetes mellitus [9e11].
Treatment of MELAS encephalopathy is based on the
assumption that energy deficit in the vascular endothelial
cells lead to impaired cerebral blood flow and reduced NO
production. Administration of NO precursors, specifically
high-dose arginine and citrulline, has been shown to improve
clinical symptoms of stroke-like episodes and to decrease the
frequency and severity of these symptoms [3,12,13]. Recent
evidence suggests that citrulline, a downstream and more
immediate precursor of NO, to be superior to arginine in
improving NO production [14]. The immediate symptomatic
relief our patient experienced on initiation of treatment, and
the excellent recovery and absence of new symptoms since
then support the NO deficiency hypothesis and the use of NO
precursors in the treatment of MELAS encephalopathy.
The combination of clinical suspicion, imaging patterns,
and genetic analysis has become the mainstay of diagnosis
and largely replaced the more invasive tissue biopsy. How-
ever, diagnosis remains challenging. Approximately 75% of
MELAS syndrome cases present before 20 years of age; disease
onset after the age of 40 years is rare and radiographic pattern
of this population is poorly documented [15]. To complicate
matters further, the focal neurologic deficits of abrupt onset
MELAS syndrome are clinically indistinguishable from an
ischemic stroke. Therefore, imaging is an essential compo-
nent of the work-up and diagnosis.
Focal hypodensities with atrophy are commonly seen on
CT scans of childhood-onset MELAS syndrome [16e18].
Global atrophy and calcification of the basal ganglia are
sometimes present [16]. MRI characteristically shows hyper-
intensity on diffusion weighted imaging and FLAIR with a
predilection for the parietal, temporal, and occipital cortex,
without conforming to a single vascular territory, a hallmark
finding of MELAS [19e21]. Blood vessels typically are normal
on angiographic evaluation, although cases of vasoconstric-
tion have been reported [22]. These diffusion signal abnor-
malities are likely to resolve over time, paralleling clinical
improvement, while new lesions may develop with or
without new symptoms. This migratory, waxing and waning
pattern of stroke-like lesions on imaging is a cardinal feature
of MELAS syndrome [16,18,23]. Pattern of ADC mapping is
variable. Recent findings suggest the initial energy insuffi-
ciency causes cytotoxic edema and reduced ADC signal
within the first 24 hours of a stroke-like episode. Develop-
ment of vasogenic edema then follows and ADC signal in-
creases within days to weeks [24]. Cortical contrast
enhancement, as a result of breakdown of the blood-brain
barrier or reperfusion hyperemia, and the subcortical hy-
permetabolic activity on PET/CT, indicate that significant
regional hyperemia is present surrounding the stroke-like
lesions. MR spectroscopy allows interrogation of tissue me-
tabolites and has proven useful in some hereditary and ac-
quired brain metabolic disorders [25e27]. The accumulation
of lactate, represented by a peak or an inverse peak at 1.3
R a d i o l o g y C a s e R e p o r t s 1 1 ( 2 0 1 6 ) 4 2 5e4 2 9 429ppm, is sensitive for MELAS encephalopathy if found in areas
that appear normal on imaging, as was seen in our patient
[23,28]. MR spectroscopy is also a potentially useful tool in
assessing treatment response in patients with MELAS syn-
drome [29].
In conclusion, our case report suggests that the radio-
graphic pattern of adult-onset MELAS syndrome is not
significantly different from the pattern in patients who pre-
sent in childhood. Migrating stroke-like lesions that do not
conform to a vascular territory is highly indicative of MELAS
syndrome. MR spectroscopy can help with the diagnosis.r e f e r e n c e s
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